PURPOSE OF REVIEW: A novel permanent carotid filter device for percutaneous implantation was developed for the purpose of stroke prevention. In this review, we cover rationale, existing preclinical and clinical data, and potential future directions for research using such a device. RECENT FINDINGS: The Vine™ filter was assessed for safety in sheep and in 2 observational human studies, the completed CAPTURE 1 (n = 25) and the ongoing CAPTURE 2 (planned n = 100). CAPTURE 1 has shown high procedural and long-term implant safety. A control group was not available for comparison. A mechanical filter for permanent stroke prevention can be implanted bilaterally in the common carotid artery safely and efficiently. A randomized trial is planned for 2021 (n = 3500, INTERCEPT) to demonstrate superiority of a filter + anticoagulation strategy over anticoagulation alone in patients at high risk for ischemic stroke.

Cardiovascular Center OLV Hospital Moorselbaan 164 B 9300 Aalst Belgium

Department of Brain Science Imperial College London London UK

Department of Cardiology Homolka Hospital Prague Czech Republic

Department of Neurology Alfried Krupp Krankenhaus Essen Germany

Department of Neurology University Heidelberg Heidelberg Germany

Helmsley Electrophysiology Center Division of Cardiology Icahn School of Medicine at Mount Sinai New York NY USA

Javelin Medical Ltd Yokne'am Israel

Population Health Research Institute McMaster University Hamilton Ontario Canada

Zobrazit více v PubMed

Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. Am J Cardiol. 2013;112(8):1142–1147. doi: 10.1016/j.amjcard.2013.05.063. PubMed DOI

Benjamin EJ, Virani SS, Callaway CW, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee et al. Heart Disease and Stroke Statistics - 2018 Update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. doi: 10.1161/CIR.0000000000000558. PubMed DOI

Yiin GSC, Li L, Bejot Y, Rothwell PM. Time trends in atrial fibrillation-associated stroke and premorbid anticoagulation. Stroke. 2019;50(1):21–27. doi: 10.1161/STROKEAHA.118.022249. PubMed DOI PMC

Lip GY. The CHA2DS2-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history. Eur Heart J. 2015;36(42):2880–2885. PubMed

Friberg L, Skeppholm M, Terént A, et al. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65:225–232. doi: 10.1016/j.jacc.2014.10.052. PubMed DOI

Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183–187. doi: 10.1016/S0735-1097(99)00489-1. PubMed DOI

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988. doi: 10.1161/01.STR.22.8.983. PubMed DOI

Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2014;36:281–288. doi: 10.1093/eurheartj/ehu307. PubMed DOI

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi: 10.7326/0003-4819-146-12-200706190-00007. PubMed DOI

• Seiffge DJ, De Marchis GM, Koga M, et al. RAF, RAF-DOAC, CROMIS-2, SAMURAI, NOACISP, Erlangen, and Verona registry collaborators. Ann Neurol. 2020. This large pooled analysis of 7 prospective studies identifies patients with stroke under anticoagulation at clear elevated risk of new recurrent stroke despite continued treatment with anticoagulation.

Xian Y, Xu H, O'Brien EC, et al. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. JAMA Neurol. 2019;22. PubMed PMC

Seiffge DJ, Paciaroni M, Wilson D, Koga M, Macha K, Cappellari M, Schaedelin S, Shakeshaft C, Takagi M, Tsivgoulis G, Bonetti B, Kallmünzer B, Arihiro S, Alberti A, Polymeris AA, Ambler G, Yoshimura S, Venti M, Bonati LH, Muir KW, Yamagami H, Thilemann S, Altavilla R, Peters N, Inoue M, Bobinger T, Agnelli G, Brown MM, Sato S, Acciarresi M, Jager HR, Bovi P, Schwab S, Lyrer P, Caso V, Toyoda K, Werring DJ, Engelter ST, de Marchis GM, on behalf of the CROMIS‐2, RAF, RAF‐DOAC, SAMURAI, NOACISP LONGTERM, Erlangen and Verona registry collaborators (CROMIS-2, RAF, RAF-DOAC, SAMURAI, NOACISP LONGTERM, Erlangen, and Verona registry collaborators). Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann Neurol. 2019;85(6):823–834. doi: 10.1002/ana.25489. PubMed DOI PMC

Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S, AVERROES Steering Committee and Investigators Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischemic attack: a predefined subgroup analysis from AVERROES, a randomized trial. Lancet Neurol. 2012;11:225–231. doi: 10.1016/S1474-4422(12)70017-0. PubMed DOI

Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC, ARISTOTLE Committees and Investigators Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11:503–511. doi: 10.1016/S1474-4422(12)70092-3. PubMed DOI

Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315–322. doi: 10.1016/S1474-4422(12)70042-X. PubMed DOI

Diener HC, Halperin JL, Fox K, Hankey GJ. Stroke prevention with rivaroxaban in higher risk populations with atrial fibrillation. Int J Clin Pract. 2015;69(7):743–756. doi: 10.1111/ijcp.12631. PubMed DOI PMC

Cavallari I, Ruff CT, Nordio F, et al. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: an analysis from the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2018;257:102–107. doi: 10.1016/j.ijcard.2018.01.065. PubMed DOI

Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2):e003074. doi: 10.1161/JAHA.115.003074. PubMed DOI PMC

Patel MR, Vellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) J Am Coll Cardiol. 2013;61(6):651–658. doi: 10.1016/j.jacc.2012.09.057. PubMed DOI

Ghoshal NG. Ruminant heart and arteries. In: Getty R, editor. Sisson & Grossman’s Anatomy of the Domestic Animals. 5th ed: W. B. Saunders; 1975. p. 1005–11.

Fisher CM. Capsular infarcts - the underlying vascular lesions. Arch Neurol. 1979;36:65–73. doi: 10.1001/archneur.1979.00500380035003. PubMed DOI

Di Carlo A, Lamassa M, Baldereschi M, European BIOMED Study of Stroke Care Group et al. Risk factors and outcome of subtypes of ischemic stroke - data from a multicenter multinational hospital-based registry. The European Community Stroke Project. J Neurol Sci. 2006;244(1–2):143–150. doi: 10.1016/j.jns.2006.01.016. PubMed DOI

Rai AT, Hogg JP, Cline B, Hobbs G. Cerebrovascular geometry in the anterior circulation: an analysis of diameter, length, and the vessel taper. J Neurointerv Surg. 2013;5(4):371–375. doi: 10.1136/neurintsurg-2012-010314. PubMed DOI

Chung EM, Hague JP, Chanrion MA, et al. Embolus trajectory through a physical replica of the major cerebral arteries. Stroke. 2010;41(4):647–652. doi: 10.1161/STROKEAHA.109.574400. PubMed DOI

Türe U, Yaşargil MG, Al-Mefty O, et al. Arteries of the insula. J Neurosurg. 2000;92(4):676–687. doi: 10.3171/jns.2000.92.4.0676. PubMed DOI

Müller HR, Brunhölzl C, Radü EW, et al. Sex and side differences of cerebral arterial caliber. Neuroradiology. 1991;33(3):212–216. doi: 10.1007/BF00588220. PubMed DOI

Han J, Qiao H, Li X, Li X, He Q, Wang Y, Cheng Z. The three-dimensional shape analysis of the M1 segment of the middle cerebral artery using MRA at 3T. Neuroradiology. 2014;56(11):995–1005. doi: 10.1007/s00234-014-1414-3. PubMed DOI

Vuillier F, Medeiros E, Moulin T, Cattin F, Bonneville JF, Tatu L. Main anatomical features of the M1 segment of the middle cerebral artery: a 3D time-of-flight magnetic resonance angiography at 3T study. Surg Radiol Anat. 2008;30(6):509–514. doi: 10.1007/s00276-008-0360-3. PubMed DOI

Muller-Hulsbeck S, et al. In vitro comparison of four cerebral protection filters for preventing human plaque embolization during carotid interventions. J Endovasc Ther. 2002;9:793–802. PubMed

Siewiorek GM, Wholey MH, Finol EA. In vitro performance assessment of distal protection filters: pulsatile flow conditions. J Endovasc Ther. 2009;16:735–743. doi: 10.1583/09-2874.1. PubMed DOI PMC

Scheel P, Ruge C, Schöning M. Flow velocity and flow volume measurements in the extracranial carotid and vertebral arteries in healthy adults: reference data and the effects of age. Ultrasound Med Biol. 2000;26(8):1261–1266. doi: 10.1016/S0301-5629(00)00293-3. PubMed DOI

Foley SR, Solano C, Simonova G, Spanevello MM, Bird RJ, Semple JW, Jackson DE, Schibler A, Fraser JF, Fung YL. A comprehensive study of ovine haemostasis to assess suitability to model human coagulation. Thromb Res. 2014;134(2):468–473. doi: 10.1016/j.thromres.2014.05.026. PubMed DOI

Connell JM, Khalapyan T, Al-Mondhiry HA, et al. Anticoagulation of juvenile sheep and goats with heparin, warfarin, and clopidogrel. ASAIO J. 2007;53(2):229–237. doi: 10.1097/MAT.0b013e31802e192b. PubMed DOI

Mottaghy K, Oedekoven B, Poppel K, et al. Heparin free long-term extracorporeal circulation using bioactive surfaces. ASAIO Trans. 1989;35(3):635–637. doi: 10.1097/00002216-198907000-00152. PubMed DOI

Berny PJ, de Oliveira LA, Videmann B, Rossi S. Assessment of ruminal degradation, oral bioavailability, and toxic effects of anticoagulant rodenticides in sheep. Am J Vet Res. 2006;67(2):363–371. doi: 10.2460/ajvr.67.2.363. PubMed DOI

Boos AM, Ringwald J, Mieth M, et al. New aspects on efficient anticoagulation and antiplatelet strategies in sheep. BMC Vet Res. 2013;9:192–219. doi: 10.1186/1746-6148-9-34. PubMed DOI PMC

Reddy VY, Sievert H, Halperin J, et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs. warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–1998. doi: 10.1001/jama.2014.15192. PubMed DOI

Holmes DR, Jr, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, Valderrabano M, Reddy VY. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65(24):2614–2623. doi: 10.1016/j.jacc.2015.04.025. PubMed DOI

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–132. doi: 10.1016/j.jacc.2019.01.011. PubMed DOI

Ruesch S, Walder B, Tramèr MR. Complications of central venous catheters: internal jugular versus subclavian access--a systematic review. Crit Care Med. 2002;30(2):454–460. doi: 10.1097/00003246-200202000-00031. PubMed DOI

Shah KB, Rao TL, Laughlin S, El-Etr AA. A review of pulmonary artery catheterization in 6,245 patients. Anesthesiology. 1984;61(3):271–275. doi: 10.1097/00000542-198409000-00007. PubMed DOI

Yilmazlar A, Bilgin H, Korfali G, Eren A, Özkan U. Complications of 1303 central venous cannulations. J R Soc Med. 1997;90(6):319–321. doi: 10.1177/014107689709000607. PubMed DOI PMC

Practical guide on left atrial appendage closure for the non-implanting physician: an international consensus paper